Yıl: 2022 Cilt: 11 Sayı: 1 Sayfa Aralığı: 1 - 14 Metin Dili: Türkçe DOI: 10.5336/pharmsci.2021-84642 İndeks Tarihi: 14-06-2022

Epilepsi Tedavisinde Klinik Kanıta Dayalı Farmakokinetik Bitkisel Ürün/Metabolit-İlaç Etkileşimi: Geleneksel Derleme

Öz:
Dünya çapında bitkisel ürün kullanımı giderek yaygınlaşmaktadır. Epilepsi hastaları, tıbbi tedavilerini tamamlamak, epilepsi yönetimini desteklemek ve nöbet sıklığını azaltmak gibi çeşitli amaçlarla bu ürünleri kullanmaya yönelmektedir. Bitkisel ürünlerin konvansiyonel ilaçlarla eş zamanlı kullanılması, bitki-ilaç etkileşimlerine yol açabilir. Bu derlemede, antiepileptik ilaçlar ile bitkisel ürünler ve bitkilerden elde edilen sekonder metabolitlerin farmakokinetik etkileşimi, 1995 ve 2016 yılları arasında gerçekleştirilen 33 klinik çalışmadan hareketle çalışmanın tipi, katılımcıların sayısı ve niteliği, bitkisel ürün ve bitkisel droglardan elde edilen sekonder metabolitler ile antiepileptik ilaçların dozu, kullanım süresi ve bitki-ilaç etkileşimine dair bulgular ele alınarak değerlendirilmiştir. Yapılan araştırmada, antiepileptik ilaçlarla klinik olarak anlamlı farmakokinetik etkileşim gösteren bitkilerin Citrus paradisi Macfad., Echinacea purpurea (L.) Moench, Ginkgo biloba L., Hydrastis canadensis L. ve Hypericum perforatum L.; sekonder metabolitlerin ise diosmin, piperin ve resveratrol olduğu görülmüştür. Çalışmanın devamında, bu bitkilerin ve sekonder metabolitlerin antiepileptik ilaçlarla olası farmakokinetik etkileşim mekanizmaları değerlendirilmiştir. Bitkisel ürünler ve sekonder metabolitler, pregnan X reseptörü aktivasyonu yoluyla sitokrom P450 enzim modülasyonu ve ilaç taşınmasında rol oynayan P-glikoprotein gibi ilaç taşıyıcı proteinleri etkilemek suretiyle antiepileptik ilaçlarla etkileşmektedir. Epilepsi tanılı bireylerde, klinikte terapötik düzeyleri takip edilen antiepileptik ilaçların kan konsantrasyon düzeylerinin subterapötik veya supraterapötik düzeylerde bulunması, durumun bitkisel ürün kullanımıyla ilişkili olduğunu göstermiştir.
Anahtar Kelime:

Clinical Evidence-Based Pharmacokinetic Herbal Product/Metabolite-Drug Interaction in the Treatment of Epilepsy:Traditional Review

Öz:
The use of herbal products is increasing worldwide. Epilepsy patients tend to use these products for various purposes such as complementing their medical treatments, supporting epilepsy management, and reducing the frequency of seizures. Simultaneous use of herbal products with conventional drugs may lead to herb-drug interactions. In this review, the pharmacokinetic interaction of antiepileptic drugs with herbal products and secondary metabolites has been evaluated in consideration of the type of the study, the number and the nature of the participants, the dose of herbal products, secondary metabolites from herbs, and antiepileptic drugs, the duration of use, the results of herb-drug interactions, based on 33 clinical studies conducted between 1995-2016. In the study, it has been observed that plants showing clinically significant pharmacokinetic interactions with antiepileptic drugs are Citrus paradisi Macfad., Echinacea purpurea (L.) Moench, Ginkgo biloba L., Hydrastis canadensis L., and Hypericum perforatum L. and the secondary metabolites are diosmin, piperine, and resveratrol. Subsequently, the possible pharmacokinetic interaction mechanisms of these plants/secondary metabolites with antiepileptic drugs were evaluated. Herbal products/secondary metabolites interact with antiepileptic drugs by affecting drug carrier proteins such as Pglycoprotein involved in cytochrome P450 enzyme modulation and drug transport through pregnane X receptor activation. The presence of subtherapeutic/supratherapeutic levels of antiepileptic drugs whose therapeutic levels are monitored clinically in individuals with epilepsy has shown that it is associated with the use of herbal products.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. World Health Organization [internet]. © 2021 WHO [Erişim tarihi: 14 Mayıs 2021]. Epilepsy. Erişim linki: [Link]
  • 2. stafstrom CE, Carmant L. seizures and epilepsy: an overview for neuroscientists. Cold spring Harb perspect Med. 2015;5(6):a022426. [Crossref] [pubMed] [pMC]
  • 3. Johnson EL. seizures and epilepsy. Med Clin North Am. 2019;103(2):309-24. [Crossref] [pubMed]
  • 4. Altındağ E, Erdoğan FF, Tezer i, Özkara ç. çocuk ve erişkin status epileptikuslu hastaya yaklaşım ve erken dönem tedavisi [Management and early treatment of status epilepticus in adults and children]. Turk J Neurol. 2017;23:155-61. [Crossref]
  • 5. Trinka E, Kälviäinen R. 25 years of advances in the definition, classification and treatment of status epilepticus. seizure. 2017;44:65-73. [Crossref] [pubMed]
  • 6. Epilepsi çalışma Grubu Tanı ve Tedavi Rehberi 2015. Türk Nöroloji Derneği. 2015. Erişim tarihi: 10 Mayıs 2021. Erişim adresi: [Link]
  • 7. Akpınar çK, Cengiz N. status epileptikus'un güncel tanı, tedavi ve etiyolojisi [Current diagnosis, treatment and etiology of status epilepticus]. Epilepsi. 2014;20(1):1-10. [Link]
  • 8. istanbulluoğlu s, çeliker A. ilaç-bitkisel ürün etkileşimlerinin önlenmesinde eczacının rolü [The role of pharmacist in prevention of drugherbal product interactions]. FABAD J pharm sci. 2018;43(3):291-305. [Link]
  • 9. World Health Organisation [internet]. WHO © 2018 [Erişim tarihi: 3 Mart 2022]. WHO Expert Committee on specifications for pharmaceutical preparations, Fifty-second report Erişim linki: [Link]
  • 10. Resmî Gazete (06.10.2010, sayı: 27721) sayılı Geleneksel Bitkisel Tıbbi Ürünler Yönetmeliği; 2010. Erişim tarihi: 20 Nisan 2021. Erişim adresi: [Link]
  • 11. Chen XW, sneed KB, pan sY, Cao C, Kanwar JR, Chew H, et al. Herbdrug interactions and mechanistic and clinical considerations. Curr Drug Metab. 2012;13(5):640-51. [Crossref] [pubMed]
  • 12. Bosak M, słowik A. Use of complementary and alternative medicine among adults with epilepsy in a university epilepsy clinic in poland. Epilepsy Behav. 2019;98(pt A):40-4. [Crossref] [pubMed]
  • 13. Işler A, Turan FD, Gözüm s, Oncel s. Complementary and alternative approaches used by parents of children with epilepsy on epilepsy management. Epilepsy Behav. 2014;32:156-61. [Crossref] [pubMed]
  • 14. Zhou s, Chan E, pan sQ, Huang M, Lee EJ. pharmacokinetic interactions of drugs with st John's wort. J psychopharmacol. 2004;18(2):262- 76. [Crossref] [pubMed]
  • 15. Wongnawa M, soontaro p, Riditid W, Wongpoowarak p, Ruengkittisakul s. The effects of Andrographis paniculata (Burm.f.) Nees on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. songklanakarin J sci Technol. 2012;34(5):533-9. [Link]
  • 16. Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, et al. Assessing the clinical significance of botanical supplementation on human cytochrome p450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin pharmacol. 2006;46(2):201-13. [Crossref] [pubMed] [pMC]
  • 17. Andersen V, pedersen N, Larsen NE, sonne J, Larsen s. Intestinal first pass metabolism of midazolam in liver cirrhosis --effect of grapefruit juice. Br J Clin pharmacol. 2002;54(2):120-4. [Crossref] [pubMed] [pMC]
  • 18. Garg sK, Kumar N, Bhargava VK, prabhakar sK. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin pharmacol Ther. 1998;64(3):286-8. [Crossref] [pubMed]
  • 19. Ozdemir M, Aktan Y, Boydag Bs, Cingi MI, Musmul A. Interaction between grapefruit juice and diazepam in humans. Eur J Drug Metab pharmacokinet. 1998;23(1):55-9. [Crossref] [pubMed]
  • 20. Kupferschmidt HH, Ha HR, Ziegler WH, Meier pJ, Krähenbühl s. Interaction between grapefruit juice and midazolam in humans. Clin pharmacol Ther. 1995;58(1):20-8. [Crossref] [pubMed]
  • 21. Bedada sK, Boga pK. Influence of diosmin on the metabolism and disposition of carbamazepine in healthy subjects. Xenobiotica. 2017;47(10):879-84. [Crossref] [pubMed]
  • 22. penzak sR, Robertson sM, Hunt JD, Chairez C, Malati CY, Alfaro RM, et al. Echinacea purpurea significantly induces cytochrome p450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. pharmacotherapy. 2010;30(8):797-805. [Crossref] [pubMed] [pMC]
  • 23. Gorski JC, Huang sM, pinto A, Hamman MA, Hilligoss JK, Zaheer NA, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome p450 activity in vivo. Clin pharmacol Ther. 2004;75(1):89-100. [Crossref] [pubMed]
  • 24. Zuo XC, Zhang BK, Jia sJ, Liu sK, Zhou LY, Li J, et al. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin pharmacol. 2010;66(5):503- 9. [Crossref] [pubMed]
  • 25. Robertson sM, Davey RT, Voell J, Formentini E, Alfaro RM, penzak sR. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin. 2008;24(2):591-9. [Crossref] [pubMed]
  • 26. Uchida s, Yamada H, Li XD, Maruyama s, Ohmori Y, Oki T, et al. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin pharmacol. 2006;46(11):1290-8. [Crossref] [pubMed]
  • 27. Gurley BJ, swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, et al. supplementation with goldenseal (Hydrastis canadensis), but not kava kava (piper methysticum), inhibits human CYp3A activity in vivo. Clin pharmacol Ther. 2008;83(1):61-9. [Crossref] [pubMed]
  • 28. Mueller sC, Majcher-peszynska J, Uehleke B, Klammt s, Mundkowski RG, Miekisch W, et al. The extent of induction of CYp3A by st. John's wort varies among products and is linked to hyperforin dose. Eur J Clin pharmacol. 2006;62(1):29-36. [Crossref] [pubMed]
  • 29. Xie R, Tan LH, polasek EC, Hong C, Teillol-Foo M, Gordi T, et al. CYp3A and p-glycoprotein activity induction with st. John's Wort in healthy volunteers from 6 ethnic populations. J Clin pharmacol. 2005;45(3):352-6. [Crossref] [pubMed]
  • 30. Gurley BJ, Gardner sF, Hubbard MA, Williams DK, Gentry WB, Cui Y, et al. Clinical assessment of effects of botanical supplementation on cytochrome p450 phenotypes in the elderly: st John's wort, garlic oil, panax ginseng and Ginkgo biloba. Drugs Aging. 2005;22(6):525-39. [Crossref] [pubMed] [pMC]
  • 31. Johne A, perloff Es, Bauer s, schmider J, Mai I, Brockmöller J, et al. Impact of cytochrome p-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. Eur J Clin pharmacol. 2004;60(9):617-22. [Crossref] [pubMed]
  • 32. Wang Ls, Zhu B, Abd El-Aty AM, Zhou G, Li Z, Wu J, Chen GL, Liu J, Tang ZR, An W, Li Q, Wang D, Zhou HH. The influence of st John's Wort on CYp2C19 activity with respect to genotype. J Clin pharmacol. 2004 Jun;44(6):577-81. [Crossref] [pubMed]
  • 33. Hall sD, Wang Z, Huang sM, Hamman MA, Vasavada N, Adigun AQ, et al. The interaction between st John's wort and an oral contraceptive. Clin pharmacol Ther. 2003;74(6):525-35. [Crossref] [pubMed]
  • 34. Gurley BJ, Gardner sF, Hubbard MA, Williams DK, Gentry WB, Cui Y, et al. Cytochrome p450 phenotypic ratios for predicting herb-drug interactions in humans. Clin pharmacol Ther. 2002;72(3):276-87. [Crossref] [pubMed]
  • 35. Wang Z, Gorski JC, Hamman MA, Huang sM, Lesko LJ, Hall sD. The effects of st John's wort (Hypericum perforatum) on human cytochrome p450 activity. Clin pharmacol Ther. 2001;70(4):317-26. [Crossref] [pubMed]
  • 36. Burstein AH, Horton RL, Dunn T, Alfaro RM, piscitelli sC, Theodore W. Lack of effect of st John's Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin pharmacol Ther. 2000;68(6):605-12. [Crossref] [pubMed]
  • 37. Chen LC, Chou MH, Lin MF, Yang LL. Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, paeoniae Radix, in healthy volunteers. J Clin pharm Ther. 2000;25(6):453-9. [Crossref] [pubMed]
  • 38. Bedada sK, Appani R, Boga pK. Effect of piperine on the metabolism and pharmacokinetics of carbamazepine in healthy volunteers. Drug Res (stuttg). 2017;67(1):46-51. [Crossref] [pubMed]
  • 39. pattanaik s, Hota D, prabhakar s, Kharbanda p, pandhi p. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy. phytother Res. 2006;20(8):683-6. [Crossref] [pubMed]
  • 40. Velpandian T, Jasuja R, Bhardwaj RK, Jaiswal J, Gupta sK. piperine in food: interference in the pharmacokinetics of phenytoin. Eur J Drug Metab pharmacokinet. 2001;26(4):241-7. [Crossref] [pubMed]
  • 41. Bano G, Amla V, Raina RK, Zutshi U, Chopra CL. The effect of piperine on pharmacokinetics of phenytoin in healthy volunteers. planta Med. 1987;53(6):568-9. [Crossref] [pubMed]
  • 42. Etman MA. Effect of a bulk forming laxative on the bioavailability of carbamazepine in man. Drug Dev Ind pharm. 1995;21(16):1901-6. [Crossref]
  • 43. Bedada sK, Nearati p. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers. phytother Res. 2015;29(5):701-6. [Crossref] [pubMed]
  • 44. Xin HW, Wu XC, Li Q, Yu AR, Xiong L. Effects of schisandra sphenanthera extract on the pharmacokinetics of midazolam in healthy volunteers. Br J Clin pharmacol. 2009;67(5):541-6. [pubMed] [pMC]
  • 45. Lilja JJ, Backman JT, Neuvonen pJ. Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYp2C9, CYp1A2, and CYp3A4. Clin pharmacol Ther. 2007;81(6):833-9. [Crossref] [pubMed]
  • 46. Razavi BM, Hosseinzadeh H. A review of the effects of Citrus paradisi (grapefruit) and its flavonoids, naringin, and naringenin in metabolic syndrome. In: Watson RR, preedy VR, eds. Bioactive Food as Dietary Interventions for Diabetes 2nd ed. London: Academic press; 2019. p.515-43. [Crossref]
  • 47. Karmakar s, Biswas s, Bera R, Mondal s, Kundu A, Ali MA, et al. Beverage-induced enhanced bioavailability of carbamazepine and its consequent effect on antiepileptic activity and toxicity. J Food Drug Anal. 2015;23(2):327-34. [Crossref] [pubMed]
  • 48. sahi J, Reyner EL, Bauman JN, Gueneva-Boucheva K, Burleigh JE, Thomas VH. The effect of bergamottin on diazepam plasma levels and p450 enzymes in beagle dogs. Drug Metab Dispos. 2002;30(2):135-40. [Crossref] [pubMed]
  • 49. Girennavar B, Jayaprakasha GK, patil Bs. potent inhibition of human cytochrome p450 3A4, 2D6, and 2C9 isoenzymes by grapefruit juice and its furocoumarins. J Food sci. 2007;72(8):C417-21. [Crossref] [pubMed]
  • 50. Aktay G, Hancı iH, Balseven A. ilaç etkileşimleri ve hekim sorumluluğu. sted. 2003;12(7):261-4. [Link]
  • 51. Ho pC, saville DJ, Wanwimolruk s. Inhibition of human CYp3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J pharm pharm sci. 2001;4(3):217-27. [pubMed]
  • 52. seden K, Dickinson L, Khoo s, Back D. Grapefruit-drug interactions. Drugs. 2010;70(18):2373-407. [Crossref] [pubMed]
  • 53. satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATp-B. Drug Metab Dispos. 2005;33(4):518-23. [Crossref] [pubMed]
  • 54. Nishimuta H, Ohtani H, Tsujimoto M, Ogura K, Hiratsuka A, sawada Y. Inhibitory effects of various beverages on human recombinant sulfotransferase isoforms sULT1A1 and sULT1A3. Biopharm Drug Dispos. 2007;28(9):491-500. [Crossref] [pubMed]
  • 55. Mochizuki K, Hamano Y, Miyama H, Arakawa K, Kobayashi T, Imamura H. successful treatment of a case with concurrent ingestion of carbamazepine overdose and grapefruit juice. Acute Med surg. 2015;3(1):36- 38. [Crossref] [pubMed] [pMC]
  • 56. Demirezer LÖ. FFD Monografları Tedavide Kullanılan Bitkiler. 1. Baskı. Ankara: Akademisyen Kitabevi Dağıtım Bil.Terc. ith. ihr.Tic. A.ş.; 2011.
  • 57. European Medicines Agency-Committee on Herbal Medicinal products [internet] EMA © [Erişim tarihi: 3 Mart 2022] Erişim linki: [Link]
  • 58. European scientific Cooperative on phytotherapy: EsCOp Monographs. The scientific Foundation for Herbal Medical products. 2nd ed. Exeter, UK: EsCOp, the European scientific Cooperative on phytotherapy; and stuttgart and New York: Thieme scientific publishers; 2003.
  • 59. Kubota Y, Kobayashi K, Tanaka N, Nakamura K, Kunitomo M, Umegaki K, et al. pretreatment with Ginkgo biloba extract weakens the hypnosis action of phenobarbital and its plasma concentration in rats. J pharm pharmacol. 2004;56(3):401-5. [Crossref] [pubMed]
  • 60. Deng Y, Bi HC, Zhao LZ, Wang XD, Chen J, Ou ZM, et al. Induction of cytochrome p450 3A by the Ginkgo biloba extract and bilobalides in human and rat primary hepatocytes. Drug Metab Lett. 2008;2(1):60-6. [Crossref] [pubMed]
  • 61. Yeung EY, sueyoshi T, Negishi M, Chang TK. Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab Dispos. 2008;36(11):2270-6. [Crossref] [pubMed] [pMC]
  • 62. satsu H, Hiura Y, Mochizuki K, Hamada M, shimizu M. Activation of pregnane X receptor and induction of MDR1 by dietary phytochemicals. J Agric Food Chem. 2008;56(13):5366-73. [Crossref] [pubMed]
  • 63. Gaudineau C, Beckerman R, Welbourn s, Auclair K. Inhibition of human p450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem Biophys Res Commun. 2004;318(4):1072-8. [Crossref] [pubMed]
  • 64. Kupiec T, Raj V. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. J Anal Toxicol. 2005;29(7):755-8. [Crossref] [pubMed]
  • 65. Granger As. Ginkgo biloba precipitating epileptic seizures. Age Ageing. 2001;30(6):523-5. [Crossref] [pubMed]
  • 66. samuels N, Finkelstein Y, singer sR, Oberbaum M. Herbal medicine and epilepsy: proconvulsive effects and interactions with antiepileptic drugs. Epilepsia. 2008;49(3):373-80. [Crossref] [pubMed]
  • 67. Chatterjee p, Franklin MR. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos. 2003;31(11):1391-7. [Crossref] [pubMed]
  • 68. Gurley BJ, Gardner sF, Hubbard MA, Williams DK, Gentry WB, Khan IA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome p450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin pharmacol Ther. 2005;77(5):415-26. [Crossref] [pubMed] [pMC]
  • 69. Etheridge As, Black sR, patel pR, so J, Mathews JM. An in vitro evaluation of cytochrome p450 inhibition and p-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. planta Med. 2007;73(8):731-41. [Crossref] [pubMed]
  • 70. Izzo AA. Interactions between herbs and conventional drugs: overview of the clinical data. Med princ pract. 2012;21(5):404-28. [Crossref] [pubMed]
  • 71. Qi JW, Nakamura K, Hosokawa s, Okada Y, Horiuchi R, Yamamoto K. Time-dependent induction of midazolam-1-hydroxylation enzymes in rats treated with st. John's wort. Biol pharm Bull. 2005;28(8):1467-71. [Crossref] [pubMed]
  • 72. Monograph. Diosmin. Altern Med Rev. 2004;9(3):308-11. [pubMed]
  • 73. Cova D, De Angelis L, Giavarini F, palladini G, perego R. pharmacokinetics and metabolism of oral diosmin in healthy volunteers. Int J Clin pharmacol Ther Toxicol. 1992;30(1):29-33. [pubMed]
  • 74. Tsujimoto M, Horie M, Honda H, Takara K, Nishiguchi K. The structureactivity correlation on the inhibitory effects of flavonoids on cytochrome p450 3A activity. Biol pharm Bull. 2009;32(4):671-6. [Crossref] [pubMed]
  • 75. Gorgani L, Mohammadi M, Najafpour GD, Nikzad M. piperine-the bioactive compound of black pepper: from isolation to medicinal formulations. Compr Rev Food sci Food saf. 2017;16(1):124-40. [Crossref] [pubMed]
APA Subaş T, GÖKKAYA İ, Özgen U, Renda G, Şahin S (2022). Epilepsi Tedavisinde Klinik Kanıta Dayalı Farmakokinetik Bitkisel Ürün/Metabolit-İlaç Etkileşimi: Geleneksel Derleme. , 1 - 14. 10.5336/pharmsci.2021-84642
Chicago Subaş Tuğba,GÖKKAYA İÇİM,Özgen Ufuk,Renda Gülin,Şahin Sevim Epilepsi Tedavisinde Klinik Kanıta Dayalı Farmakokinetik Bitkisel Ürün/Metabolit-İlaç Etkileşimi: Geleneksel Derleme. (2022): 1 - 14. 10.5336/pharmsci.2021-84642
MLA Subaş Tuğba,GÖKKAYA İÇİM,Özgen Ufuk,Renda Gülin,Şahin Sevim Epilepsi Tedavisinde Klinik Kanıta Dayalı Farmakokinetik Bitkisel Ürün/Metabolit-İlaç Etkileşimi: Geleneksel Derleme. , 2022, ss.1 - 14. 10.5336/pharmsci.2021-84642
AMA Subaş T,GÖKKAYA İ,Özgen U,Renda G,Şahin S Epilepsi Tedavisinde Klinik Kanıta Dayalı Farmakokinetik Bitkisel Ürün/Metabolit-İlaç Etkileşimi: Geleneksel Derleme. . 2022; 1 - 14. 10.5336/pharmsci.2021-84642
Vancouver Subaş T,GÖKKAYA İ,Özgen U,Renda G,Şahin S Epilepsi Tedavisinde Klinik Kanıta Dayalı Farmakokinetik Bitkisel Ürün/Metabolit-İlaç Etkileşimi: Geleneksel Derleme. . 2022; 1 - 14. 10.5336/pharmsci.2021-84642
IEEE Subaş T,GÖKKAYA İ,Özgen U,Renda G,Şahin S "Epilepsi Tedavisinde Klinik Kanıta Dayalı Farmakokinetik Bitkisel Ürün/Metabolit-İlaç Etkileşimi: Geleneksel Derleme." , ss.1 - 14, 2022. 10.5336/pharmsci.2021-84642
ISNAD Subaş, Tuğba vd. "Epilepsi Tedavisinde Klinik Kanıta Dayalı Farmakokinetik Bitkisel Ürün/Metabolit-İlaç Etkileşimi: Geleneksel Derleme". (2022), 1-14. https://doi.org/10.5336/pharmsci.2021-84642
APA Subaş T, GÖKKAYA İ, Özgen U, Renda G, Şahin S (2022). Epilepsi Tedavisinde Klinik Kanıta Dayalı Farmakokinetik Bitkisel Ürün/Metabolit-İlaç Etkileşimi: Geleneksel Derleme. Literatür Eczacılık Bilimleri Dergisi, 11(1), 1 - 14. 10.5336/pharmsci.2021-84642
Chicago Subaş Tuğba,GÖKKAYA İÇİM,Özgen Ufuk,Renda Gülin,Şahin Sevim Epilepsi Tedavisinde Klinik Kanıta Dayalı Farmakokinetik Bitkisel Ürün/Metabolit-İlaç Etkileşimi: Geleneksel Derleme. Literatür Eczacılık Bilimleri Dergisi 11, no.1 (2022): 1 - 14. 10.5336/pharmsci.2021-84642
MLA Subaş Tuğba,GÖKKAYA İÇİM,Özgen Ufuk,Renda Gülin,Şahin Sevim Epilepsi Tedavisinde Klinik Kanıta Dayalı Farmakokinetik Bitkisel Ürün/Metabolit-İlaç Etkileşimi: Geleneksel Derleme. Literatür Eczacılık Bilimleri Dergisi, vol.11, no.1, 2022, ss.1 - 14. 10.5336/pharmsci.2021-84642
AMA Subaş T,GÖKKAYA İ,Özgen U,Renda G,Şahin S Epilepsi Tedavisinde Klinik Kanıta Dayalı Farmakokinetik Bitkisel Ürün/Metabolit-İlaç Etkileşimi: Geleneksel Derleme. Literatür Eczacılık Bilimleri Dergisi. 2022; 11(1): 1 - 14. 10.5336/pharmsci.2021-84642
Vancouver Subaş T,GÖKKAYA İ,Özgen U,Renda G,Şahin S Epilepsi Tedavisinde Klinik Kanıta Dayalı Farmakokinetik Bitkisel Ürün/Metabolit-İlaç Etkileşimi: Geleneksel Derleme. Literatür Eczacılık Bilimleri Dergisi. 2022; 11(1): 1 - 14. 10.5336/pharmsci.2021-84642
IEEE Subaş T,GÖKKAYA İ,Özgen U,Renda G,Şahin S "Epilepsi Tedavisinde Klinik Kanıta Dayalı Farmakokinetik Bitkisel Ürün/Metabolit-İlaç Etkileşimi: Geleneksel Derleme." Literatür Eczacılık Bilimleri Dergisi, 11, ss.1 - 14, 2022. 10.5336/pharmsci.2021-84642
ISNAD Subaş, Tuğba vd. "Epilepsi Tedavisinde Klinik Kanıta Dayalı Farmakokinetik Bitkisel Ürün/Metabolit-İlaç Etkileşimi: Geleneksel Derleme". Literatür Eczacılık Bilimleri Dergisi 11/1 (2022), 1-14. https://doi.org/10.5336/pharmsci.2021-84642